You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 19, 2024

Details for Patent: 9,539,328


✉ Email this page to a colleague

« Back to Dashboard


Title:Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
Abstract: The present disclosure provides an extended release pharmaceutical composition comprising hydrocodone and acetaminophen that provides a rapid onset of analgesia, and reduced levels of acetaminophen near the end of the dosing interval. Also provided are methods for reducing the risk of acetaminophen-induced hepatic damage in a subject being treated with an acetaminophen containing composition, as well as methods for treating pain in a subject in need thereof.
Inventor(s): Devarakonda; Krishna (St. Louis, MO), Giuliani; Michael J. (Creve Coeur, MO), Gupta; Vishal K. (Hillsborough, NJ), Heasley; Ralph A. (Webster Groves, MO), Shelby; Susan (Town and Country, MO)
Assignee: MALLINCKRODT LLC (Hazelwood, MO)
Filing Date:Sep 05, 2014
Application Number:14/479,129
Claims:1. An extended release pharmaceutical composition, comprising: an immediate release portion comprising hydrocodone or a pharmaceutically acceptable salt of hydrocodone, acetaminophen, or a combination thereof; and an extended release portion comprising hydrocodone or a pharmaceutically acceptable salt of hydrocodone, acetaminophen, or a combination thereof; wherein the total amount of acetaminophen in the composition is from about 325 mg to about 650 mg and the total amount of hydrocodone or a pharmaceutically acceptable salt thereof in the composition is from about 7.5 mg to about 15 mg; wherein when the composition is orally administered to a subject in need thereof the composition delivers the hydrocodone or the pharmaceutically acceptable salt thereof and the acetaminophen to the subject's upper gastrointestinal tract for at least about 4 hours to about 12 hours; and wherein there is substantially no effect on AUC.sub.0-inf for hydrocodone and acetaminophen when the pharmaceutical composition is administered in a fed versus fasted state.

2. The extended release pharmaceutical composition of claim 1, wherein the extended release component comprises at least one extended release polymer.

3. The extended release pharmaceutical composition of claim 2, wherein the at least one extended release polymer is a polyethylene oxide.

4. The extended release pharmaceutical composition of claim 3, wherein the polyethylene oxide has a molecular weight from about 500,000 Daltons to about 10,000,000 Daltons.

5. The extended release pharmaceutical composition of claim 1, wherein the total amount of the acetaminophen in the composition is about 325 mg; and the total amount of the hydrocodone or a pharmaceutically acceptable salt thereof in the composition is about 7.5 mg.

6. The extended release pharmaceutical composition of claim 1, wherein the composition is administered to a subject in need thereof at least twice a day.

7. The extended release pharmaceutical composition of claim 1, wherein the composition delivers the hydrocodone or the pharmaceutically acceptable salt thereof and the acetaminophen to the subject's upper gastrointestinal tract for at least about 6 hours.

8. A method of treating pain in a patient in need thereof, comprising administering to the patient the pharmaceutical composition of claim 1.

9. The method of claim 8, wherein the subject in need thereof is suffering from pain or diagnosed with a condition associated with pain, the pain being acute pain or chronic pain.

10. The method of claim 9, wherein the subject in need thereof is suffering from moderate to severe acute pain.

11. An extended release pharmaceutical composition comprising: at least one immediate release portion comprising hydrocodone or a pharmaceutically acceptable salt thereof and acetaminophen and at least one extended release portion comprising an extended release component, hydrocodone or a pharmaceutically acceptable salt thereof, and acetaminophen; wherein the at least one immediate release portion comprises from about 20% to about 30% (w/w) of the total amount of the hydrocodone or a pharmaceutically acceptable salt thereof, and about 40% to about 60% (w/w) of the total amount of the acetaminophen in the composition; wherein the sum of the amounts of the acetaminophen in the immediate release and the extended release portions is about 325 mg; wherein the sum of the amounts of the hydrocodone or pharmaceutically acceptable salt thereof in the immediate release and extended release portions is about 7.5 mg; and wherein the composition can be administered to a subject in need thereof without regard to food.

12. The extended release composition of claim 11, wherein the AUC of hydrocodone when a subject is in a fasted state is bioequivalent to the AUC of hydrocodone when the subject is in a fed state.

13. The extended release composition of claim 11, wherein the AUC of acetaminophen when a subject is in a fasted state is bioequivalent to the AUC of acetaminophen when the subject is in a fed state.

14. The extended release composition of claim 11, wherein the C.sub.max of hydrocodone when a subject is in a fasted state is bioequivalent to the C.sub.max of hydrocodone when the subject is in a fed state.

15. The extended release composition of claim 11, wherein there is substantially no effect on AUC.sub.0-inf for hydrocodone and acetaminophen when the composition is administered in a fed versus fasted state.

16. A pharmaceutical composition comprising an immediate release portion and an extended release portion, wherein: the immediate release portion comprises acetaminophen and hydrocodone or a pharmaceutically acceptable salt thereof, the extended release comprises acetaminophen, hydrocodone or a pharmaceutically acceptable salt thereof, and an extended release component, and the total amount of acetaminophen in the pharmaceutical composition is from about 325 mg to about 650 mg and the total amount of hydrocodone or a pharmaceutically acceptable salt thereof in the pharmaceutical composition is from about 7.5 mg to about 15 mg, wherein the pharmaceutical composition provides an AUC.sub.(0-3hr) for hydrocodone after a single dose from about 1.0 nghr/mL/mg to about 5.0 nghr/mL/mg.

17. The pharmaceutical composition of claim 16, wherein upon oral administration, the pharmaceutical composition provides an AUC.sub.(0-3hr) for hydrocodone from about 1.50 nghr/mL/mg to about 4.25 nghr/mL/mg.

18. The pharmaceutical composition of claim 16, wherein upon oral administration, the pharmaceutical composition provides an AUC.sub.(0-3hr) for hydrocodone from about 2.0 nghr/mL/mg to about 3.0 nghr/mL/mg.

19. The pharmaceutical composition of claim 16, wherein upon oral administration, the pharmaceutical composition provides an AUC.sub.0-12hr for hydrocodone from about 5 nghr/mL/mg to about 25 nghr/mL/mg.

20. The pharmaceutical composition of claim 16, wherein upon oral administration, the pharmaceutical composition provides an AUC.sub.0-12hr for hydrocodone from about 7.5 nghr/mL/mg to about 15.5 nghr/mL/mg.

21. The pharmaceutical composition of claim 16, wherein upon oral administration, the pharmaceutical composition provides an AUC.sub.0-12hr for hydrocodone from about 8.5 nghr/mL/mg to about 12.5 nghr/mL/mg.

22. The pharmaceutical composition of claim 16, wherein upon oral administration, the pharmaceutical composition provides an AUC.sub.1-12hr for hydrocodone from about 3 nghr/mL/mg to about 20 nghr/mL/mg.

23. The pharmaceutical composition of claim 16, wherein upon oral administration, the pharmaceutical composition provides an AUC.sub.1-12hr for hydrocodone from about 7.5 nghr/mL/mg to about 15.0 nghr/mL/mg.

24. The pharmaceutical composition of claim 16, wherein upon oral administration, the pharmaceutical composition provides an AUC.sub.1-12hr for hydrocodone from about 8 nghr/mL/mg to about 12.5 nghr/mL/mg.

25. The pharmaceutical composition of claim 16, wherein upon oral administration, the pharmaceutical composition provides an AUC.sub.8-12hr for hydrocodone from about 1 nghr/mL/mg to about 6 nghr/mL/mg.

26. The pharmaceutical composition of claim 16, wherein upon oral administration, the pharmaceutical composition provides an AUC.sub.8-12hr for hydrocodone from about 2 nghr/mL/mg to about 5 nghr/mL/mg.

27. The pharmaceutical composition of claim 16, wherein upon oral administration, the pharmaceutical composition provides an AUC.sub.8-12hr for hydrocodone from about 3 nghr/mL/mg to about 4 nghr/mL/mg.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.